Final FDA OK for Mylan's generic of B-MS' Metaglip
Generic drugmaker Mylan Pharmaceuticals has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for glipizide and metformin HCl tablets in 2.5mg/250 mg, 2.5mg/500mg and 5mg/500mg strengths.
This is the generic version of Bristol-Myers Squibb's Metaglip, which generated US sales of around $29.0 million for the same strengths during the 12-month period ended December 31, 2006, according to IMS Health.
Announcing the news on April 13, Mylan said it will start shipping the product immediately.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze